Amicus Therapeutics Inc. (FOLD)

15.17
NASDAQ : Health Technology
Prev Close 15.83
Day Low/High 14.76 / 15.83
52 Wk Low/High 5.87 / 17.40
Avg Volume 2.45M
Exchange NASDAQ
Shares Outstanding 166.27M
Market Cap 2.46B
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

U.S. FDA Files New Drug Application Under Priority Review For Migalastat For Treatment Of Fabry Disease

U.S. FDA Files New Drug Application Under Priority Review For Migalastat For Treatment Of Fabry Disease

Six-Month PDUFA Goal Date is August 13, 2018

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

Outside of oncology, the rare disease area is a good target for M&A in 2018.

Circle These Biotech Acquisition Candidates

Circle These Biotech Acquisition Candidates

Outside of oncology, the rare disease area is a good target for M&A in 2018.

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.

10 Biotech Stocks to Watch in 2018

10 Biotech Stocks to Watch in 2018

There are a variety of players that should be active in the M&A space next year.

Biotech Stocks to Watch: Part 1

Biotech Stocks to Watch: Part 1

Upcoming catalysts will redefine the biotech market -- and here are 3 names that will feel the impact.

Amicus Therapeutics Appoints Michael C. Diem, MD As Senior Vice President Of Business And Corporate Development

Amicus Therapeutics Appoints Michael C. Diem, MD As Senior Vice President Of Business And Corporate Development

Driven Business Executive with Strong Industry Track Record

Mylan Soars After FDA Approval for Generic Copaxone --Biotech Movers

Mylan Soars After FDA Approval for Generic Copaxone --Biotech Movers

The pharmaceutical company on Oct. 3 said the FDA has approved its generic version of Teva's multiple sclerosis drug Copaxone.

Bank Funds Fall Short on the Upside

After Fed decision, buying interest looks weak.

U.S. FDA Grants Orphan Drug Designation For ATB200/AT2221 For Pompe Disease

U.S. FDA Grants Orphan Drug Designation For ATB200/AT2221 For Pompe Disease

New Phase 1/2 Clinical Data to be Presented at World Muscle Society

Remember, Fed News Is a Trigger for the Computers

Remember, Fed News Is a Trigger for the Computers

So I'm staying focused on stock picking.

U.S. FDA Grants Fast Track Designation For Amicus Therapeutics' Migalastat For Treatment Of Fabry Disease

U.S. FDA Grants Fast Track Designation For Amicus Therapeutics' Migalastat For Treatment Of Fabry Disease

New Drug Application Submission on Track for 4Q17

Strong Action in Individual Stocks Starts to Feel a Bit Frothy

Strong Action in Individual Stocks Starts to Feel a Bit Frothy

It's hard to predict when momentum will slow, but it could be time to take some profits when the market is as strong as this morning.

Amicus Therapeutics Announces Approval For Galafold™ (Migalastat) For Treatment Of Fabry Disease In Canada

Amicus Therapeutics Announces Approval For Galafold™ (Migalastat) For Treatment Of Fabry Disease In Canada

First Oral Precision Medicine for Fabry Disease with Broad Label for Fabry Patients with Amenable Genetic Mutations

The Flippers Are at Work and the Bears Are Hopeful

The Flippers Are at Work and the Bears Are Hopeful

Apple and its suppliers are dragging the market down.

Portola Shares Lower After Pricing Stock Offering - Biotech Movers

Portola Shares Lower After Pricing Stock Offering - Biotech Movers

The South San Francisco, Calif.-based firm said Sept. 12 it had priced its underwritten public offering of 6.35 million shares at $55 apiece.

TheStreet Quant Rating: D- (Sell)